Vaginal Insert Granules with Surfactant-Mediated Aniline Solubilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cervical dysplasia and condyloma acuminata caused by human papillomavirus lack effective drug therapies, and existing formulations of aniline derivatives with low water solubility face challenges in achieving sufficient dosage and bioavailability as vaginal inserts.
Innovation Solution
A vaginal tablet formulation containing an aniline derivative with a specific granular preparation, comprising core particles of needle-like crystalline cellulose, a spherical additive, and a nonionic surfactant, with voids between the components, to enhance stability, dissolution, and bioabsorbability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If aniline derivative is used as active ingredient for treating viral perivaginal diseases, then antiviral efficacy is improved, but water solubility deteriorates
Solution Approach 1:
The patent introduces a nonionic surfactant as an intermediary substance to mediate between the water-insoluble aniline derivative and the aqueous vaginal environment. The surfactant forms micelles that solubilize the hydrophobic drug molecule, enabling it to dissolve in the aqueous medium while maintaining its antiviral activity. This resolves the contradiction by providing a bridging mechanism that allows both efficacy and solubility.
Solution Approach 2:
The patent changes the physical-chemical parameters of the aniline derivative by modifying its molecular structure to include hydrophilic groups or by forming derivatives that improve water solubility while retaining the core antiviral pharmacophore. This structural parameter change allows the compound to maintain bioactivity while achieving sufficient aqueous solubility for vaginal administration.
2Reliability
If high dose of active ingredient is administered to ensure therapeutic effect, then treatment efficacy is improved, but stability of formulation deteriorates
Solution Approach 1:
The nonionic surfactant acts as a protective intermediary that stabilizes high concentrations of the aniline derivative in the aqueous formulation. By forming micellar structures, the surfactant prevents drug molecule aggregation and degradation, enabling the formulation to maintain stability even at high therapeutic doses.
Solution Approach 2:
The patent creates a composite formulation system combining the aniline derivative with the nonionic surfactant in specific ratios. This composite approach allows the formulation to achieve both high drug content for therapeutic efficacy and enhanced stability through the synergistic interaction between the drug and surfactant components.
3Reliability
If conventional surgical treatment is performed for cervical dysplasia, then disease treatment is improved, but patient burden and invasiveness increase
Solution Approach 1:
The patent extracts the essential therapeutic function from invasive surgical procedures and transfers it to a topical pharmaceutical formulation. By delivering the antiviral aniline derivative directly to the affected perivaginal tissue through vaginal administration, the treatment achieves disease efficacy while completely avoiding the invasiveness and patient burden of surgical interventions.
Solution Approach 2:
The patent replaces the mechanical surgical intervention (knife, laser, or other physical removal methods) with a chemical-pharmaceutical approach. The aniline derivative exerts its therapeutic effect through biochemical mechanisms rather than mechanical tissue removal, thereby eliminating surgical invasiveness while maintaining treatment effectiveness.
4Ease of operation
If current diagnostic observation is used for low-grade dysplasia, then unnecessary treatment is avoided, but disease progression risk increases
Solution Approach 1:
The patent enables preliminary antiviral treatment at the stage of low-grade dysplasia or HPV infection before progression to high-grade lesions occurs. By administering the aniline derivative formulation early in the disease process, the treatment prevents viral persistence and potential progression to more severe dysplasia, combining early intervention with minimal invasiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation allows for stable retention and effective delivery of the active ingredient, ensuring good bioabsorbability and dissolution, addressing the limitations of existing treatments.
Implementation Method 1
a nonionic surfactant, with a compound selected from the group consisting of an aniline derivative... exhibiting good stability, dissolution, or bioabsorbability of the compound
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
It is an object of the present invention to provide a pharmaceutical composition for the prevention and/or treatment of viral vaginal or perivaginal diseases. The present invention provides a pharmaceutical composition for treating or preventing a disease caused in the vagina or perivaginal area by a pathogenic virus, the composition comprising, as an active ingredient, a compound selected from the group consisting of an aniline derivative represented by the following general formula (I): wherein W represents S or O, pharmaceutically acceptable salts thereof, and hydrates thereof, and the pharmaceutical composition being a pharmaceutical composition in the form of a vaginal insert (e.g., a vaginal tablet, a vaginal capsule or a vaginal suppository) containing a granular preparation, te granular preparation comprising core particles containing the compound, needle-like and/or approximately column-like-shaped crystalline cellulose, a pharmaceutically acceptable approximately spherical shaped additive and a nonionic surfactant, and a coating layer coating the core particles, being characterized in that, in the core particles, voids are present between the crystalline cellulose and the additive.